5 Questions
What was the key eligibility criteria for patients in the trial?
Age of 18 to 85 years, diagnosis of ATTR cardiac amyloidosis, evidence of cardiac involvement, and history of heart failure
What was the role of Adelphi Communications in the preparation of the manuscript?
Provided editorial assistance
Who vouched for the accuracy and completeness of the data and the fidelity of the trial to the protocol?
All the authors who had access to the data
What was a key exclusion criterion for patients in the trial?
New York Heart Association (NYHA) class of III and an ATTR amyloidosis stage of 3
What were some patients receiving at baseline, and what were others not receiving?
Some patients were receiving tafamidis, and others were not receiving it
Test your knowledge of the latest medical research with this quiz on the Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis, as published in the New England Journal of Medicine. Assess your understanding of the study's findings and the implications for treating this condition.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
